Lazard Asset Management
AVNS

Lazard Asset Management’s Avanos Medical AVNS Stock Holding History

Lazard Asset Management’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-282,642
Closed -$3.96M – 1956
2026
Q1 		$3.96M Buy
282,642
+30,954
+12% +$417K 0.01% 627
2025
Q4 		$2.83M Sell
251,688
-4,891
-2% -$56K ﹤0.01% 734
2025
Q3 		$2.97M Buy
256,579
+18,964
+8% +$222K ﹤0.01% 736
2025
Q2 		$2.91M Buy
237,615
+231,344
+3,689% +$2.91M ﹤0.01% 889
2025
Q1 		$89K Buy
+6,271
New +$97.9K ﹤0.01% 1838
2023
Q4 		– Sell
-7,053
Closed -$142K – 2250
2023
Q3 		$142K Buy
7,053
+828
+13% +$18.8K ﹤0.01% 1502
2023
Q2 		$159K Hold
6,225
– – ﹤0.01% 1413
2023
Q1 		$185K Hold
6,225
– – ﹤0.01% 1330
2022
Q4 		$168K Buy
6,225
+575
+10% +$14.1K ﹤0.01% 1336
2022
Q3 		$123K Buy
+5,650
New +$148K ﹤0.01% 1395
2022
Q2 		– Sell
-37,818
Closed -$1.27M – 2379
2022
Q1 		$1.27M Buy
+37,818
New +$1.22M ﹤0.01% 965
2020
Q4 		– Sell
-1,318
Closed -$43K – 1842
2020
Q3 		$43K Buy
+1,318
New +$42.1K ﹤0.01% 1226
2019
Q4 		– Sell
-592,564
Closed -$22.2M – 1527
2019
Q3 		$22.2M Sell
592,564
-23,267
-4% -$888K 0.04% 322
2019
Q2 		$26.9M Sell
615,831
-65,054
-10% -$2.78M 0.04% 292
2019
Q1 		$29.1M Buy
680,885
+144,440
+27% +$6.47M 0.05% 250
2018
Q4 		$24M Buy
536,445
+88,525
+20% +$4.64M 0.04% 260
2018
Q3 		$30.7M Buy
447,920
+55,310
+14% +$3.56M 0.05% 244
2018
Q2 		$22.5M Buy
+392,610
New +$20.7M 0.04% 292
2016
Q4 		– Sell
-20,949
Closed -$726K – 990
2016
Q3 		$726K Buy
+20,949
New +$734K ﹤0.01% 700
2015
Q3 		– Sell
-100
Closed -$4K – 1085
2015
Q2 		$4K Sell
100
-11,266
-99% -$506K ﹤0.01% 1090
2015
Q1 		$559K Sell
11,366
-263
-2% -$12.2K ﹤0.01% 754
2014
Q4 		$528K Buy
+11,629
New +$457K ﹤0.01% 818

Other funds holding AVNS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Lazard Asset Management's AVNS Position: Q2 2026 in Review

Lazard Asset Management sold out of Avanos Medical (AVNS) in Q2 2026, closing a stake of 282,642 shares — an estimated $3.96M sold.

Lazard Asset Management first reported a position in AVNS in Q4 2014 and held it in 22 quarters. The position peaked at $30.7M in Q3 2018. 286 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

  • Lazard Asset Management reported no remaining Avanos Medical position as of Q2 2026 after selling out during the quarter.
  • Lazard Asset Management sold 282,642 Avanos Medical shares in Q2 2026, an estimated $3.96M.
  • Lazard Asset Management first reported a position in Avanos Medical in Q4 2014 and held it in 22 quarters.
  • Lazard Asset Management's Avanos Medical position peaked at $30.7M in Q3 2018.
  • 286 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.